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peptides from tumor cells or from MHC molecules puri-
fied from tumor cells and to detect fractions capable
of stimulating antitumor T cells after pulsing purified
fractions onto antigen-presenting cells. Triple quadra-
pole mass spectrometric techniques have then been
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Bethesda, Maryland 20892 used to sequence the minute quantities of peptides ob-
tained (Cox et al., 1994). This approach has been se-
verely limited by the need for custom-made, highly spe-
In 1929, reviewing the available information concerning cialized equipment and the requirement that peptides
cancer immunotherapy, W. H. Woglom wrote, ªIt would be present in sufficient quantity to enable their identifi-
be as difficult to reject the right ear and leave the left cation by these physical techniques.
ear intact as it is to immunize against cancerº (1929). The ability of antigen-presenting cells to endocytose
Minimal progress had been made since the earliest de- proteins and present peptides on class II MHC mole-
scriptions of attempts to immunize against cancer by cules has been utilized to identify antigens recognized
Nooth, the surgeon to the Duke of Kent, who in 1777 by CD4 T cells, although thus far few antigens have been
inoculated himself with cancer tissue, or the physician identified using this approach (Topalian et al., 1994).
to Louis XVIII, who in 1808 injected himself with breast Each of the three techniques mentioned above is de-
cancer tissue. Knowledge of the cellular immune system pendent on the prior availability of T cells capable of
was sparse, and as late as 1958 the Journal of Immunol- recognizing tumor antigens, a requirement that often
ogy did not list the word ªlymphocyteº in its index. Most cannot be met. A fourth approach to the identification
attempts to develop cancer vaccines involved immuni- of tumor antigens has involved attempts to develop, by
zation of cancer patients using either their own or alloge- in vitro sensitization techniques, T cells against candi-
neic tumors along with a variety of nonspecific immune date tumor antigens (Parkhurst et al., 1998). T cells suc-
adjuvants. Even as the basic tenets of modern cellular cessfully generated in vitro against candidate antigens
immunology were elucidated, studies of cancer immu- have then been tested for their ability to recognize intact
notherapy languished at the periphery of respectable tumor cells, and the presence of such reactivity provides
science due to a lack of information regarding the molec- strong evidence that these candidate proteins represent
ular identification of the components of the putative tumor antigens. Genes encoding candidate tumor anti-
immune reaction against human cancers. gens have been transfected or transduced into antigen-
In the past decade, however, the convergence of infor- presenting cells or synthesized peptides from candidate
mation from basic studies of cellular and molecular im- antigens based on known MHC-binding motifs have
munology and the application of recombinant DNA tech- been pulsed onto antigen-presenting cells and used for
niques to produce pharmacologic quantities of biologic these in vitro sensitizations.
molecules normally present only in minute amounts An alternate technique for the identification of tumor
have substantially changed views concerning the im- antigens that is also not dependent on the prior availabil-
mune response to human cancer and have provided ity of antitumor T cells has recently been described. This
the first demonstrations that immune reactions against approach, called serological analysis of recombinant
cancer antigens can lead to the regression of invasive cDNA expression libraries (SEREX), uses diluted serum
tumors in selected patients. The molecular identification from cancer patients to detect prokaryotically ex-
of tumor antigens, their immunodominant peptides, and pressed cDNA libraries prepared from tumors (Sahin et
the T cell receptors that recognize them have placed al., 1995; Chen et al., 1997). This approach is based on
studies of tumor immunology and immunotherapy in the the assumption that antibody production implies that a
mainstream of immunologic research. helper T cell reaction exists against the detected anti-
gen. At least one tumor antigen, NY-ESO-1, subse-
quently shown to be reactive with CD81 T cells, hasMethods for the Detection of Tumor Antigens
been identified using this approach (Chen et al., 1997),Four major techniques have been used to identify cancer
and other candidate antigens are being studied (Tureciantigens capable of eliciting cellular immune reactions
et al., 1996).in humans. The majority of human tumor antigens now
known have been identified by the transfection of geno-
Characteristics of Tumor Antigensmic DNA or cDNA libraries into cells expressing the
An unexpected diversity of mechanisms can result in theappropriate MHC molecule, followed by the identifica-
generation of antigenic epitopes recognized by tumor-tion of transfectants using cytokine release or lysis by
specific T cells. These epitopes have come from normalhuman T cells with specific antitumor reactivity (Boon,
nonmutated genes whose expression is limited to can-1993; Rosenberg, 1996). Biochemical approaches have
cer and selected normal tissues, from aberrantly ex-had more limited success in the identification of human
pressed intronic sequences, from alternative open read-cancer antigens. Attempts have been made to elute
ing frames of normal genes, and from mutations specific
to the individual cancer (Table 1).
Malignant melanomas have been a particularly rich* E-mail: sar@nih.gov.
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react with differing peptides derived from a variety ofTable 1. Defined Cancer Antigens
exogenous antigens including viral proteins, and cross-
Antigen Category Gene MHC Restriction reactivity with these epitopes may result in the high
Melanocyte MART-1/MelanA A2, B45 precursor frequency of T cells against the MART-1 epi-
differentiation gp100 A2, A3, A24 tope (Loftus et al., 1996).
Tyrosinase A1, A2, A24, DR4 Of the 29 HLA-A2-reactive TIL, 13 reacted with the
TRP-1 A31 gp100 melanoma differentiation antigen (Kawakami et
TRP-2 A2, A31, A68
al., 1994b). This 661±amino acid protein was identifiedCancer testis MAGE-1 A1, Cw16
independently by screening cDNA expression librariesMAGE-3 A1, A2, B44
GAGE-1/2 Cw16 with melanoma reactive lymphocytes (Kawakami et al.,
BAGE Cw16 1994b) as well as by elution of peptides from an HLA-
RAGE B7 A21 melanoma (Cox et al., 1994). This gene had pre-
NY-ESO-1 A2, A31 viously been isolated and was known to encode a pro-
Tumor specific CDK-4 A2
tein recognized by the HMB-45 monoclonal antibodyb-catenin A24
but was unknown as a T cell antigen. The gp100 pro-MUM-1 B44
Caspase-8 B35 tein encodes an enzyme involved in melanin synthesis,
KIAA0205 B44 and multiple gp100 epitopes have been identified re-
HPVE7 A2 stricted not only by HLA-A2 but by HLA-A3 and HLA-
Widely expressed SART-1 A26 A24 as well (Kawakami et al., 1995; Skipper et al., 1996b;
PRAME A24
Robbins et al., 1997; Tsai et al., 1997; Kawakami etp15 A24
al., 1998). Interestingly, the epitope recognized by HLA-
A24-restricted T cells results from an aberrantly spliced
product of the gp100 gene, resulting in translation of
the fourth intron of the gp100 molecule in both melano-source of tumor antigens that are found not only on
mas and in normal melanocytes (Robbins et al., 1997).melanomas but on other tumor types as well. Two major
Tyrosinase, an enzyme critical for the synthesis ofcategories of normal, non-mutated genes that encode
melanin, has been shown to be an antigen recognizedshared tumor antigens have been identified: (1) differen-
by HLA-A1-, HLA-A2-, and HLA-A24-restricted T cellstiation antigens shared on melanomas and melanocytes,
(Brichard et al., 1993; Robbins et al., 1994; Wolfel etand (2) differentiation antigens shared on a variety of
al., 1994; Kittlesen et al., 1998). One of the naturallytumors as well as normal testes.
occurring peptide epitopes restricted by HLA-A2 con-The expression of one family of differentiation anti-
tains a posttranslational modification of an asparaginegens is limited to melanomas as well as melanocytes,
to aspartic acid residue (Skipper et al., 1996a). Tyrosi-the cell of origin of this tumor, and pigment-producing
nase is the only melanoma/melanocyte differentiationcells in the retina. The T cells used to identify these mela-
antigen known to be recognized by CD41 tumor-reactivenoma/melanocyte differentiation antigens have largely
T cells (Topalian et al., 1994). A CD41 tumor-infiltratingbeen derived from tumor-infiltrating lymphocytes (TIL)
lymphocyte cross-reactive with HLA-DR04011 melano-obtained from patients with growing cancers or from
mas was used to test for reactivity against candidateautologous mixed-lymphocyte tumor cultures (Boon,
melanoma antigens previously shown to be recognized1993; Rosenberg, 1996). The presence of precursors
by CD81 T cells, and tyrosinase was identified as thecapable of reacting with normal nonmutated self-anti-
reactive antigen. Several class II±presented epitopesgens within the tumor has suggested that the inflam-
from tyrosinase have also been identified.matory microenvironment at the site of the tumor has
Two melanocyte proteins that bear approximatelyresulted in the breaking of peripheral tolerance to these
40% amino acid homology to tyrosinase have been iden-antigens. Alternatively, the tumor may have acted as
tified as T cell antigens (Wang et al., 1995, 1996, 1998a).a ªsinkº for the accumulation of precursors normally
TRP-1 is the most prevalent protein present in melano-present, since precursors to at least one of these anti-
cytes and melanomas and was recognized as a tumorgens has also been found in normal individuals.
antigen reactive with HLA-A31-restricted TIL 586 fromThe most common antitumor reactivity found in mela-
a patient with melanoma. The peptide epitope reactivenoma patients is directed against the MART-1/MelanA
with TIL 586 was encoded by the normal TRP-1 geneantigen, which is a 118±amino acid protein of unknown
but was not translated from the primary open readingfunction that contains a 21±amino acid transmembrane
frame (Wang et al., 1996). The third open reading frameregion (Coulie et al., 1994; Kawakami et al., 1994a). The
immunodominance of this antigen in HLA-A2 individuals of this gene translated a 21±amino acid peptide that
contained the 9±amino acid peptide epitope recognizedis striking (Kawakami et al., 1994c). Of 29 HLA-A21 TIL
exhibiting HLA-A2-restricted recognition of shared tu- by TIL 586. This alternative open reading frame was also
translated in normal melanocytes. At least one othermor antigens, 21 reacted with the MART-1 protein. In
all 21 cases, these TIL recognized the identical 9-mer example of an alternative open reading frame encoding
a tumor antigen was subsequently described (Wang etAAGIGILTV peptide. A MART-1 epitope has also been
identified that is restricted by HLA-B45 (Schneider et al., 1998b), and rare other examples exist of the recogni-
tion of the products of alternative open reading framesal., 1998). Responses to the MART-1/MelanA epitope
can be readily elicited in vitro from peripheral lympho- (Malarkannan et al., 1995; Quelle et al., 1995; Elliott et
al., 1996; Bullock et al., 1997). Clones from TIL 586 alsocytes of normal nonmelanoma-containing individuals
(Marincola et al., 1996). MART-1-reactive T cells can recognized TRP-2 as an HLA-A31-restricted antigen,
Review
283
and an epitope from the normal open reading frame of (Chen et al., 1997). Although this antigen was originally
identified by its ability to react with a naturally occurringthis protein was identified (Wang et al., 1998a). TRP-1
and TRP-2 epitopes can bind to HLA-A3, -A11, -A31, antibody, this gene product was subsequently found to
be reactive with T cells as well. By screening clones-A3, and -A68 (Sidney et al., 1996; Wang et al., 1998a).
Studies of the TRP-2 protein represent an example of from melanoma TIL 586, the NY-ESO-1 gene was inde-
pendently identified and found to encode two differentthe use of in vitro sensitization techniques to identify new
tumor antigenic epitopes. To identify HLA-A2-restricted epitopes restricted by HLA-A31, with one encoded by
an alternative open reading frame of the NY-ESO-1 geneTRP-2 epitopes, multiple peptides were synthesized
from the TRP-2 protein based on HLA-A2-binding mo- (Wang et al., 1998b). Approximately 10% of patients
develop high-titer antibodies against NY-ESO-1 (Stock-tifs. Using in vitro sensitization techniques against those
multiple peptides, an HLA-A2-restricted T cell was gen- ert et al., 1998) and an HLA-A2-restricted CTL line from
a melanoma patient with a high titer of antibodies toerated against a single TRP-2 peptide, SVYDFFVWL,
that was also capable of recognizing HLA-A21 melano- NY-ESO-1 was also found to react with the NY-ESO-1
protein. Two HLA-A2-restricted epitopes have beenmas (Parkhurst et al., 1998).
Thus, at least five melanoma/melanocyte differentia- identified (Jager et al., 1998). NY-ESO-1 appears to be
expressed only in the testes and in a wide variety oftion proteins have been shown to mediate the generation
of T cells capable of recognizing melanomas restricted tumors including melanomas and cancers of the ovary,
bladder, breast, prostate, and lung (Chen et al., 1997;by multiple class I alleles.
Another class of shared differentiation antigens is ex- Stockert et al., 1998).
The melanocyte/differentiation antigens and the can-pressed on tumors as well as germ cells of the testes.
The first cloned human tumor antigen recognized by T cer/testis antigens represent the majority of tumor anti-
gens thus far identified that are encoded by normalcells was isolated utilizing T cells from a melanoma
patient who had been repeatedly immunized with muta- nonmutated genes. A class of poorly understood tumor
antigens encoded by genes that are widely expressedgenized cancer cells (Van der Bruggen et al., 1991). The
T cells from this individual were sensitized in vitro to in normal tissues but appear to be selectively presented
on tumor cells has been described as well. An HLA-the autologous melanoma, and reactive T cell clones
that recognized a protein encoded by a gene termed A24-restricted TIL line reactive with HLA-A24 melano-
mas was used to isolate a previously undescribed geneMAGE-1 were identified. This gene belonged to a multi-
gene family containing at least 12 different genes ex- called p15 (Robbins et al., 1995). Although Northern
blots revealed that p15 was expressed in normal tissues,pressed in a small percentage of melanomas as well
as cancers arising in the breast, prostate, esophagus, only tumor was recognized by this TIL. The mechanisms
involved in this unique tumor recognition have not yetcolon, and lung (Brasseur et al., 1992; Traversari et al.,
1992; Boon, 1993; Weynants et al., 1994; Van Pel et al., been elucidated. The SART-1 gene had similar charac-
teristics and was recognized in lung and esophageal1995). Except for testes, the gene does not appear to
be expressed in normal tissues. The MAGE-3 gene in this squamous cell carcinomas but was also expressed in
normal proliferating cell lines (Shichijo et al., 1998). Thefamily is of particular interest because it is expressed in
a high percentage of melanomas and head and neck PRAME gene product, reactive with T cells restricted
by HLA-A24 that expressed an NK inhibitory receptor,squamous cell carcinomas (Gaugler et al., 1994; Van
Den Eynde and Van der Bruggen, 1997). was identified only when the tumor lost the appropriate
HLA-Cw7 class I molecule that limited recognition ofBy screening cDNA libraries utilizing T cell clones from
the same patient used to identify the MAGE gene family, these tumor cells (Lehmann et al., 1995). This gene was
expressed in low levels in a variety of normal tissues,another series of multigene families called BAGE (Boel
et al., 1995) and GAGE (Van Den Eynde et al., 1995) have with much greater levels of expression in melanomas.
It is thus clear that a variety of normal nonmutated genesalso been identified. These gene products appear to
have similar expression distributions to the MAGE gene can result in the generation of T cells reactive with tu-
mors. These genes come from normal differentiationfamily. Epitopes from the MAGE, GAGE, and BAGE
genes have been identified that are restricted by HLA- proteins, from translated alternative open reading frames,
and from nonmutated intronic sequences. T cells recog-A1, -A2, -B44, and -Cw16 (Traversari et al., 1992; Gaugler
et al., 1994; Van der Bruggen et al., 1994a, 1994b; nizing these gene products are capable of reacting with
a variety of tumor types.Fleischauer et al., 1996; Tanaka et al., 1997). This family
of tumor antigens was detected using in vitro sensitized Based on murine tumor models, in which in vivo tumor
protection appeared to be unique to the individual im-T cells from the autologous patient, although no descrip-
tions of TIL recognizing these antigens have yet been munizing tumor, it was expected that human tumor anti-
gens would represent the products of mutated genes.reported. The levels of MAGE-1 expressed by some
tumor cells can be below the level of detection required A variety of gene mutations that give rise to tumor anti-
genic epitopes in the human have now been described.for lymphocyte recognition (Lethe et al., 1997), even
though some studies suggest that as few as five pep- An HLA-B44-restricted T cell was identified that recog-
nized the product of a gene termed MUM-1 (Coulie ettides on the cell surface are sufficient for T cell recogni-
tion (Brower et al., 1994; Sykulev et al., 1996). al., 1995). The epitope recognized by this T cell spanned
an intron/exon boundary and contained a single baseAnother antigen expressed in cancers and testes is
the NY-ESO-1 antigen that was identified by screening mutation. The normal and mutated peptides bound
equally to HLA-B44, and thus the mutation appeared toa melanoma cDNA expression library using serum from a
patient with squamous cell carcinoma of the esophagus alter a T cell contact residue.
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An HLA-A2-restricted CTL clone was found to recog- mediating tumor regression when adoptively transferred
to cancer patients (Kawakami et al., 1995; Rosenberg,nize the mutated product of a cyclin-dependent kinase
1997). An analysis of HLA-A2-restricted TIL transferred4 (CDK4) gene (Wolfel et al., 1995). A single base muta-
to melanoma patients demonstrated a statistically sig-tion in this gene resulted in the substitutions of a cyste-
nificant correlation of tumor destruction in vivo and rec-ine for an arginine in an anchor position of this peptide
ognition of the gp100 tumor antigen (Kawakami et al.,and altered the binding properties of this peptide to
1995). This association was not seen for TIL reactiveHLA-A2. One hundred±fold lower concentrations of the
with the MART-1 antigen. Further evidence for the rolemutant peptide compared to the native peptide were
of these melanoma/melanocyte antigens in tumor de-recognized.
struction comes from studies of depigmentation (vitiligo)A mutation in the a-helical region of the HLA-A2 mole-
in cancer patients (Rosenberg and White, 1996). No viti-cule gave rise to a mutated epitope recognized by T
ligo was seen in 102 patients with renal cell cancercells reactive with an autologous renal cell carcinoma
treated with IL-2 compared to a 16% incidence of vitiligo(Brandle et al., 1996). Similarly, a point mutation in a
in 73 similarly treated melanoma patients. There was nogene encoding a protein recognized by T cells reactive
evidence of depigmentation seen in melanoma patientswith an autologous bladder carcinoma resulted in the
who did not respond to this immunotherapy comparedunique recognition of the autologous tumor cell line
with vitiligo in 29% of patients who showed an antican-(Gueguen et al., 1998). A single point mutation in the
cer response (p2 5 0.002). Thus, tumor destruction wasnormal stop code encoding the caspase-8 gene resulted
associated with the destruction of normal melanocytes,in the extension of the normal open reading frame of
strongly suggesting that the targets in tumor and normalthis gene by 88 amino acids, and a T cell epitope was
tissue were the melanoma/melanocyte differentiationencoded within this region that was recognized by the
antigens.T cells of the autologous patient with a squamous cell
The downregulation of expression of antigens maycarcinoma (Mandruzzato et al., 1997). A TIL that recog-
represent a problem for the development of immuno-nized an HLA-A24 melanoma antigen was found to rec-
therapies because of the possible immunoselection ofognize a mutated b-catenin gene product. A single point
nonexpressing tumor clones. For this reason an idealmutation that substituted a phenylalanine for a serine
target for immune destruction is a protein that is essen-residue gave rise to a peptide epitope that was recog-
tial for the malignant phenotype, and mutations that givenized at 1 million times lower concentration than the
rise to antigens in such proteins have been described.normal peptide (Robbins et al., 1996). The same muta-
The antigenic mutation in CDK4 appeared to disrupt thetion in b-catenin was found at about 10% of all melano-
binding of the normal CDK4 inhibitor, p16-INK4a, andmas examined (Rubinfeld et al., 1997).
disruption of this interaction may have contributed to
unregulated tumor cell growth (Wolfel et al., 1995; Sherr,Development of Cancer Immunotherapy Based
1996). Loss of expression of this mutation would thuson the Identification of Tumor Antigens
presumably reverse the malignant phenotype. Similarly,Leonardo da Vinci (1452±1519) wrote that ªthe supreme
the mutated caspase-8 gene product may play a role in
misfortune is when theory outstrips performance,º a sit-
the apoptic pathway and thus be involved in tumorigene-
uation that now characterizes the current state of cancer
sis (Mandruzzato et al., 1997). The mutated b-catenin
immunotherapy. The discovery of tumor antigens and
gene product in selected HLA-A24 melanomas ap-
the identification of their immunodominant epitopes has peared to stabilize the b-catenin molecule and promote
shifted emphasis to the utilization of these antigens to the formation of complexes with the Tcf family of DNA-
mediate the destruction of growing cancers in humans. binding proteins, which may activate target genes in
Attempts are in progress to develop immunotherapies tumorigenesis (Robbins et al., 1996; Korinek et al., 1997;
based on the specific stimulation of immune reactions Rubinfeld et al., 1997; Morin et al., 1999).
against defined tumor antigens rather than on the non- Although the mutated proteins may be attractive tar-
specific stimulation of the immune system that has char- gets for cancer immunotherapy, they will be appropriate
acterized prior approaches. Although studies of the ad- only for the individual patients expressing these muta-
ministration of interleukin-2 to cancer patients have tions and thus will not be suitable for the development
demonstrated that broad stimulation of immune reactiv- of widely applicable cancer immunotherapies. Improve-
ity can lead to the complete and partial regression of ments in methods to identify tumor-associated muta-
even bulky invasive tumors in humans, these clinical tions recognized by the immune system, however, leave
effects are limited to a small number of patients with open the possibility of tailoring individual immunothera-
limited histologic types of cancers (Rosenberg et al., pies for individual cancer patients.
1994, 1998a). Cancer immunotherapy based either on The development of cancer immunotherapies based
immunization against specific tumor antigens or on the on the molecular characterization of tumor antigens is
adoptive transfer of in vitro generated lymphocytes with in its early stages, and only a small number of clinical
high levels of specific reactivity against tumor antigens trials have been reported. Immunization of patients us-
represent attractive approaches. ing recombinant avipox, vaccinia virus, or adenovirus
Which tumor antigens represent the best targets for encoding cancer antigens have thus far not resulted in
the development of effective immunotherapies? Several consistent in vivo generation of antitumor T cells or
lines of evidence exist that the melanoma/melanocyte clinical responses, probably due in part to the potent
differentiation antigens can be effective targets for the generation of neutralizing antibodies directed against
immune destruction of melanoma. TIL reactive with de- the viral envelope proteins (Tsang et al., 1995; Rosen-
berg et al., 1998b; Marshall et al., 1999). Preliminaryfined melanoma/melanocyte antigens are capable of
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evidence has suggested that immunization with native however, arrived based on the molecular identification
of human cancer antigens.or modified (heteroclitic) peptides derived from tumor
antigens may be a more promising means of immuniza-
Referencestion. Of 12 patients immunized with the soluble HLA-A1-
binding MAGE-3 peptide, 2 patients exhibited a partial
Boel, P., Wildmann, C., Sensi, M.L., Brasseur, R., Renauld, J.C.,tumor regression, although there was no evidence for Coulie, P., Boon, T., and Van der Bruggen, P. (1995). BAGE: a new
the generation of CTL in the peripheral blood of treated gene encoding an antigen recognized on human melanomas by
patients (Marchand et al., 1995). Although no clinical cytolytic T lymphocytes. Immunity 2, 167±175.
responses were seen in six patients immunized with Boon, T. (1993). Tumor antigens recognized by cytolytic T lympho-
cytes: present perspectives for specific immunotherapy. Int. J. Can-HLA-A2-restricted peptides from MART-1, tyrosinase,
cer 54, 177±180.and gp100 antigens, a modest enhancement of in vitro
Brandle, D., Brasseur, F., and Weynants, P. (1996). A mutated HLA-antipeptide responses were seen (Jager et al., 1996a).
A2 molecule recognized by autologous cytotoxic T lymphocytes onThese same workers, however, provided preliminary evi-
a human renal cell carcinoma. J. Exp. Med. 183, 2501±2508.dence that the addition of GM-CSF administration to
Brasseur, F., Marchand, M., Vanwijck, R., Herin, M., Lethe, B., Cho-the vaccine regimen mediated tumor regression in three
mez, P., and Boon, T. (1992). Human gene MAGE-1, which codes
patients (Jager et al., 1996b) and that the clinical impact for a tumor-rejection antigen, is expressed by some breast tumors.
of immune reactions induced by peptide immunization Letter to the editor. Int. J. Cancer 52, 839±841.
may be limited by the expression of antigens by the Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe,
B., Coulie, P., and Boon, T. (1993). The tyrosinase gene codes fortumor (Jager et al., 1996c).
an antigen recognized by autologous cytolytic T lymphocytes onTwo recently reported clinical trials, however, have
HLA-A2 melanomas. J. Exp. Med. 178, 489±495.provided encouraging information concerning the ability
Brower, R.C., England, R., and Takeshita, T. (1994). Minimal require-of peptide immunization to mediate tumor regression.
ments for peptide mediated activation of CD81 CTL. Mol. Immunol.
Patients (10 of 11) immunized with a peptide from the 31, 1285±1293.
gp100 molecule gp100:209±217 (210M), modified to in- Bullock, T.N., Patterson, A.E., Notidis, E., Franlin, L.L., and Eisenlohr,
crease binding to HLA-A2, showed a substantial induc- L.C. (1997). Initiation codon scanthrough versus termination codon
tion of circulating precursors capable of reacting not readthrough demonstrates strong potential for major histocompati-
bility complex class I-restricted cryptic epitope expression. J. Exp.only with the native peptide but with HLA-A2-matched
Med. 186, 1051±1058.tumors (Rosenberg et al., 1998c). Although no significant
Chen, Y.T., Scanlan, M.J., and Sahin, U. (1997). A testicular antigenclinical responses were seen in these 11 patients, objec-
aberrantly expressed in human cancers detected by autologoustive clinical responses were seen in 13 of 42 patients who
antibody screening. Proc. Natl. Acad. Sci. USA 94, 1914±1918.
received this modified gp100:209±217 (210M) peptide in
Coulie, P., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traver-
conjunction with IL-2 (Rosenberg et al., 1998c). This sari, C., Mattei, S., DePlaen, E., Lurquin, C., Szikora, J., et al. (1994).
response rate was three times that expected from the A new gene coding for a differentiation antigen recognized by autol-
ogous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med.use of IL-2 alone, and prospective randomized trials
180, 35±42.comparing the treatment of patients with metastatic
Coulie, P.G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., An-melanoma using either IL-2 alone or IL-2 plus peptide
drawiss, M., and Boon, T. (1995). A mutated intron sequence codesimmunization are being initiated. In another clinical trial,
for an antigenic peptide recognized by cytolytic T lymphocytes on
16 patients with metastatic melanoma were immunized a human melanoma. Proc. Natl. Acad. Sci. USA 92, 7976±7980.
with dendritic cells pulsed either with immunodominant Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Sha-
melanoma peptides or with melanoma lysates, and ob- banowitz, J., Engelhard, V.H., Hunt, D.F., and Slingluff, C.L. (1994).
jective tumor regression was reported in five patients Identification of a peptide recognized by five melanoma-specific
human cytotoxic T cell lines. Science 264, 716±719.(Nestle et al., 1998). Multiple other approaches to the
Elliott, T., Bodmer, H., and Townsend, A. (1996). Recognition of out-active immunization of patients using the products of
of-frame major histocompatibility complex class I-restricted epi-these tumor antigen genes are being explored, including
topes in vivo. Eur. J. Immunol. 26, 1175±1179.immunization with peptides, intact protein, ªnakedº
Fleischauer, K., Fruci, D., and Van Endert, P. (1996). CharacterizationDNA, and recombinant adenovirus, vaccinia virus, and
of antigenic peptides presented by HLA-B44 molecules on tumor
fowlpox virus encoding these tumor antigens. The ex cells expressing the gene MAGE-3. Int. J. Cancer 68, 622±628.
vivo exposure of antigen-presenting cells to antigenic Gaugler, B., Van Den Eynde, B., Van der Bruggen, P., Romero, P.,
proteins or peptides and the administration of immune- Gaforio, J.J., De Plaen, E., Lethe, B., Brassuer, F., and Boon, T.
(1994). Human gene MAGE-3 codes for an antigen recognized onenhancing cytokines such as IL-2 and IL-12 in conjunc-
a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med.tion with these immunizations is also being explored in
179, 921±930.experimental models and in human clinical trials.
Gueguen, M., Matard, J.J., and Gaugler, B. (1998). An antigen recog-In vitro sensitization techniques using repeated in vitro
nized by autologous CTLs on a human bladder carcinoma. J. Immu-
stimulation against immunodominant peptides or utiliz- nol. 160, 6188±6194.
ing tumor antigens pulsed onto professional antigen- Jager, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Kar-
presenting cells have resulted in the in vitro generation bach, J., Ilsemann, C., Hagedorn, M., and Knuth, A. (1996a). Genera-
tion of cytotoxic T-cell responses with synthetic melanoma-associ-of T cells with extremely high antitumor activity, and
ated peptides in vivo: implications for tumor vaccines withclinical protocols utilizing the adoptive transfer of these
melanoma-associated antigens. Int. J. Cancer 66, 162±169.in vitro sensitized cells are in progress as well.
Jager, E., Ringhoffer, M., Dienes, H.P., Arand, M., Karbach, J., Jager,Marshalling the immune response to reject human
D., Ilsemann, C., Hagedorn, M., Oesch, F., and Knuth, A. (1996b).
tumors is a daunting challenge, although not as difficult Granulocyte-macrophage-colony-stimulating factor enhances im-
as the need to ªreject the right ear and leave the left mune responses to melanoma-associated peptides in vivo. Int. J.
Cancer 67, 54±62.ear intact.º A new era of cancer immunotherapy has,
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Jager, E., Ringhoffer, M., and Karbach, J. (1996c). Inverse relation- patients of a replication-defective avipox recombinant vaccine that
expresses human carcinoembryonic antigen. J. Clin. Oncol. 17,ship of melanocyte differentiation antigen expression in melanoma
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